KCK LTD.

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed July 11, 2025), KCK LTD. reported 2 stock positions worth $10.5 million. Its top holding was Sight Sciences (SGHT) at 99.6% of the portfolio, followed by Rein Therapeutics (RNTX, 0.4%). Compared with Q4 2024, it sold out of 1. The biggest sale was an exit from Neuropace (NPCE).

Most Recent 13F
Q3 2025
Location
HAMILTON, D0
CIK
0001657662
Portfolio Value
$10.5M (Q1 2025)
SEC Filing
0001657662-25-000013 ↗ filed Jul 11, 2025

Holdings Value

0$20.0M$40.0M$60.0M$80.0M Q4 2024: $75.0M Q4 2024 Q1 2025: $10.5M $10.5M Q1 2025 Q2 2025: $18.3M Q2 2025 Q3 2025: $15.1M Q3 2025

Holdings 2 stocks · $10.5M
SGHT Sight Sciences Inc. 99.62% 4,374,975 $10.5M No change
RNTX Rein Therapeutics Inc. 0.38% 22,341 $40K No change

Portfolio Sells Q4 2024 → Q1 2025
NPCE Neuropace Inc. Sold out 0.00% −78.69

Portfolio Buys Q4 2024 → Q1 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 2$15.1MSGHT, RNTX
Q2 2025 2$18.3MSGHT, RNTX
Q1 2025 2$10.5MSGHT, RNTX
Q4 2024 3$75.0MNPCE, SGHT, RNTX